- Hologic’s projected adjusted EPS for the second quarter is $1.00 to $1.03, slightly below the estimate of $1.04.
- The company maintains its full-year adjusted EPS forecast between $4.25 and $4.35, aligning with analysts’ estimate of $4.25.
- First-quarter adjusted EPS reached $1.03, surpassing the anticipated $1.01.
- First-quarter revenue matched expectations at $1.02 billion.
- The adjusted gross margin for the first quarter was 61.6%, higher than the estimated 60.6%.
- The adjusted net margin was reported at 23.4%, slightly above the projected 23.2%.
- The company credits strong profitability and effective capital allocation strategy for maintaining its full-year EPS guidance.
- Analyst ratings for Hologic include 8 buys, 13 holds, and 1 sell.
Hologic Inc on Smartkarma
Analysts on Smartkarma are closely watching Hologic Inc‘s latest moves, with insights from Baptista Research shedding light on the company’s performance. In one report titled “Expanding Diagnostic Assay Portfolio For A Competitive Edge! – Major Drivers,” Hologic’s financial results for the fourth quarter and fiscal year 2024 are analyzed. The report highlights a 4.2% increase in total revenue to $987.9 million, with organic revenue growth excluding COVID-related sales at 5%. Additionally, non-GAAP earnings per share saw a 13.5% growth to $1.01, showcasing both strengths and challenges for the company.
Another report by Baptista Research, titled “Hologic Inc.: Breast Health Innovations,” focuses on the company’s strong performance in the third quarter of fiscal 2024. With total revenue reaching $1.01 billion and non-GAAP earnings per share at $1.06, Hologic exceeded their guidance predictions. This notable revenue growth of 3.1% compared to the previous year signifies a solid recovery path post-pandemic challenges, including those posed by COVID-19 and global disruptions like the chip shortage, demonstrating strategic efficiency and resilience in the market.
A look at Hologic Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Hologic Inc appears to have a mixed long-term outlook. While the company scores moderately in areas such as value, growth, resilience, and momentum, it lags behind in the dividend category with a score of 1. Hologic Inc specializes in premium diagnostic products, medical imaging systems, and surgical products, with core business units dedicated to diagnostics, breast health, GYN surgical, and skeletal health.
The company’s scores of 3 in value, growth, resilience, and momentum indicate promising prospects in these areas, suggesting potential for future growth and stability. However, the low dividend score of 1 may deter income-focused investors. Overall, Hologic Inc‘s focus on diagnostic products and medical imaging systems positions it well for sustained growth, despite some areas for improvement identified by the Smartkarma Smart Scores.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
